S8040 — Topographic brain mapping
HCPCS/CPT
Prior Authorization
No Prior Auth Required
No active coverage policies found for this code (low confidence)
Medicare Pricing
Work RVU
0.00
Facility
N/A
Non-Facility
N/A
Documentation Required
- Document rationale and baseline measures if pursuing complementary or investigational therapies (neurofeedback, dietary interventions, supplementation) and obtain informed consent discussing limited evidence and uncertainties.
- When pharmacologic therapy is used, document medication trials, doses, response and adverse effects where relevant (discussion of stimulants, atomoxetine, bupropion, TCAs appears in the evidence review).
- EndeavorRx: requirement implied in indication — documentation of patient age (8 to 12 years), ADHD subtype (primarily inattentive or combined-type), and a "demonstrated attention issue" measurable by computer-based testing (e.g., baseline computer-based attention testing).
- AKL-T01 (as studied): documentation used in trials included psychiatric screening, ADHD ratings, baseline neuropsychological measures, and objective attentional performance measures such as the TOVA Attention Performance Index (API) with trial inclusion requiring TOVA API ≤ -1.8.
Key Coverage Criteria
- "EndeavorRx is a digital therapeutic (video game-based) indicated to improve attention function as measured by computer-based testing in children aged 8 to 12 years with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue."
- EndeavorRx: "should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder."
- AKL-T01 (investigational digital therapeutic): indicated in study context to target attention and cognitive control in pediatric patients with ADHD (studied in children aged 8 to 12 years in STARS-ADHD RCT and aged 8 to 14 in adjunct study STARS-Adjunct).
- AKL-T01 (study-specified objective inclusion): pediatric patients with confirmed ADHD and TOVA Attention Performance Index (API) scores of -1.8 and below (STARS-ADHD trial).
- Extended-release methylphenidate: discussed as the "recommended 1st-line pharmacological treatment" for adults with ADHD (Cochrane review examined extended-release formulations in adults diagnosed with ADHD).
- Tryptophan modulation: investigated in clinical trials for effects on ADHD-related symptoms (evidence insufficient; trials mainly used acute tryptophan depletion procedures).
9 Active Policies
AMBETTER-CP.BH.124 — Attention Deficit Hyperactivity Disorder Assessment and Treatment
AETNA-CPB-0221 — Quantitative EEG (Brain Mapping)
AETNA-CPB-0426 — Attention Deficit/Hyperactivity Disorder
ANTHEM-MED.00002 — MED.00002 Selected Sleep Testing Services
BCBSIL-MED205.040 — Quantitative Electroencephalography as a Diagnostic Aid for Attention-Deficit/Hyperactivity Disorder, Cognitive Impairment, or Autism Spectrum Disorder
Related Codes
Have a follow-up question?
Ask Verity about documentation requirements, denial risks, or coverage in your state.